Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 (vol 15, pg 429, 2009)

被引：2
|
作者：
Junttila, Teemu T. [1 ]
Akita, Robert W. [1 ]
Parsons, Kathryn [1 ]
Fields, Carter [1 ]
Phillips, Gail D. Lewis [1 ]
Friedman, Lori S. [1 ]
Sampath, Deepak [1 ]
Sliwkowski, Mark X. [1 ]
机构：
[1] Genentech Inc, Res Oncol, San Francisco, CA 94080 USA
来源：
CANCER CELL | 2011年 / 20卷 / 06期
关键词：
D O I：
10.1016/j.ccr.2011.12.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：818 / 818
页数：1
相关论文
共 50 条
  • [1] Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
    Junttila, Teemu T.
    Akita, Robert W.
    Parsons, Kathryn
    Fields, Carter
    Phillips, Gail D. Lewis
    Friedman, Lori S.
    Sampath, Deepak
    Sliwkowski, Mark X.
    CANCER CELL, 2009, 15 (05) : 429 - 440
  • [2] Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
    Yao, Evelyn
    Zhou, Wei
    Lee-Hoeflich, Si Tuen
    Truong, Tom
    Haverty, Peter M.
    Eastham-Anderson, Jeffrey
    Lewin-Koh, Nicholas
    Gunter, Bert
    Belvin, Marcia
    Murray, Lesley J.
    Friedman, Lori S.
    Sliwkowski, Mark X.
    Hoeflich, Klaus P.
    CLINICAL CANCER RESEARCH, 2009, 15 (12) : 4147 - 4156
  • [3] A HER3 antibody that blocks ligand-independent HER2-HER3 dimerization sensitizes to HER2 and PI3K inhibitors.
    Garrett, Joan T.
    Sutton, Cammie R.
    Bialucha, Carl Uli
    Ettenberg, Seth A.
    Wallweber, Jerry
    DeFazio-Eli, Lisa
    Arteaga, Carlos L.
    CANCER RESEARCH, 2013, 73 (08)
  • [4] HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3
    Ruiz-Saenz, Ana
    Dreyer, Courtney
    Campbell, Marcia R.
    Steri, Veronica
    Gulizia, Nate
    Moasser, Mark M.
    CANCER RESEARCH, 2018, 78 (13) : 3645 - 3658
  • [5] The PI3K inhibitor GDC-0941 combines with trastuzumab for superior anti-tumor efficacy in HER2+breast cancer models
    De, P.
    Sun, Y.
    Carlson, J.
    Friedman, L.
    Dey, N.
    Leyland-Jones, B.
    CANCER RESEARCH, 2013, 73
  • [6] GDC-0941 PI3K inhibitor activity in preclinical lung cancer models
    Friedman, L.
    Belvin, M.
    Berry, L.
    Haverty, P.
    Hoeflich, K.
    Lackner, M.
    Sampath, D.
    Wallin, J.
    Yauch, B.
    EJC SUPPLEMENTS, 2010, 8 (07): : 51 - 51
  • [7] PI3K Signaling Pathway Activation Predicts Class I PI3K Inhibitor GDC-0941 Sensitivity in AML.
    Ma, Xiaoju Max
    Du, Changchun
    Sun, Laura
    Shi, Xiaoyan
    Friedman, Lori
    Doman, David
    Ebens, Allen J.
    BLOOD, 2009, 114 (22) : 437 - 437
  • [8] More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro
    Zheng, Jie
    Wang, Huan
    Yao, Jia
    Zou, Xianjin
    PHARMAZIE, 2014, 69 (01): : 38 - 42
  • [9] Radiosensitisation properties of PI3K/AKT inhibitor GDC-0941 in prostate cancer cells
    Floyd, R.
    McDermott, N.
    Meunier, A.
    Marignol, L.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S572 - S572
  • [10] Mechanisms of acquired resistance to the PI3K inhibitor GDC-0941 in breast cancer cell lines
    Edgar, Kyle A.
    Hwu, Ling
    Walter, Kimberly
    Lackner, Mark
    Friedman, Lori S.
    Wallin, Jeffrey J.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
12345